ATE396205T1 - Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe - Google Patents

Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe

Info

Publication number
ATE396205T1
ATE396205T1 AT99936898T AT99936898T ATE396205T1 AT E396205 T1 ATE396205 T1 AT E396205T1 AT 99936898 T AT99936898 T AT 99936898T AT 99936898 T AT99936898 T AT 99936898T AT E396205 T1 ATE396205 T1 AT E396205T1
Authority
AT
Austria
Prior art keywords
therapeutic agents
peptides
peptide derivatives
derivatives
peptide
Prior art date
Application number
AT99936898T
Other languages
English (en)
Inventor
Jacques Theze
Ralph Eckenberg
Jean-Louis Moreau
Michel Goldberg
Thierry Rose
Pedro Alzari
Jean-Claude Mazie
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE396205T1 publication Critical patent/ATE396205T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99936898T 1998-07-16 1999-07-16 Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe ATE396205T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/116,594 US6168785B1 (en) 1998-07-16 1998-07-16 Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE396205T1 true ATE396205T1 (de) 2008-06-15

Family

ID=22368127

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99936898T ATE396205T1 (de) 1998-07-16 1999-07-16 Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe

Country Status (11)

Country Link
US (4) US6168785B1 (de)
EP (1) EP1097173B1 (de)
AT (1) ATE396205T1 (de)
AU (1) AU5186799A (de)
CA (1) CA2337511A1 (de)
CY (1) CY1108610T1 (de)
DE (1) DE69938786D1 (de)
DK (1) DK1097173T3 (de)
ES (1) ES2308845T3 (de)
PT (1) PT1097173E (de)
WO (1) WO2000004048A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6929791B2 (en) 1998-07-16 2005-08-16 Institut Pasteur Peptides of IL-2 and derivatives thereof
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7662368B2 (en) * 1999-07-16 2010-02-16 Institut Pasteur Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
CA2493019A1 (en) * 2002-08-06 2004-02-19 Aplagen Gmbh Binding molecules
ATE401345T1 (de) * 2002-08-06 2008-08-15 Aplagen Gmbh Synthetische mimetika von physiologischen bindungsmolekülen
EP1694360B1 (de) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat-abstossung
US7943294B2 (en) 2004-07-30 2011-05-17 Hologic, Inc. Methods for detecting oncofetal fibronectin
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9901731B2 (en) * 2006-01-31 2018-02-27 Medtronic, Inc. Medical electrical lead having improved inductance
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
US10114018B2 (en) 2014-04-22 2018-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) IL-2 peptide derivatives, and uses thereof for the diagnosis and treatment of an autoimmune disease
MA47290A (fr) 2015-10-08 2019-11-27 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
CN112399859B (zh) 2018-05-21 2024-11-29 尼克塔治疗公司 选择性TREG刺激剂RUR20kD-IL-2和相关组合物
KR20210025522A (ko) 2018-06-25 2021-03-09 유니버시티 오브 워싱톤 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
EP3883956A1 (de) 2018-11-20 2021-09-29 University of Washington Gespaltene interleukin-mimetika und deren verwendung
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
MX2024007345A (es) 2021-12-14 2024-09-30 Nektar Therapeutics Pautas posologicas para el estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738927A (en) * 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
JPH03500415A (ja) * 1988-07-05 1991-01-31 アムジエン・インコーポレーテツド インターロイキン２類似体
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
CU22222A1 (es) * 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents

Also Published As

Publication number Publication date
ES2308845T3 (es) 2008-12-01
US7101965B2 (en) 2006-09-05
US6825334B1 (en) 2004-11-30
DE69938786D1 (de) 2008-07-03
US6168785B1 (en) 2001-01-02
WO2000004048A1 (en) 2000-01-27
PT1097173E (pt) 2008-08-26
DK1097173T3 (da) 2008-09-01
CY1108610T1 (el) 2014-04-09
EP1097173B1 (de) 2008-05-21
US20040202661A1 (en) 2004-10-14
EP1097173A1 (de) 2001-05-09
CA2337511A1 (en) 2000-01-27
US6596853B1 (en) 2003-07-22
AU5186799A (en) 2000-02-07

Similar Documents

Publication Publication Date Title
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE69807074D1 (de) Substituierte 1,2,4-triazolo[3,4,-a]phthalazin-derivate als gaba-alpha 5-liganden
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DE60032486D1 (de) Prion protein peptide und deren verwendung
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
ATE280777T1 (de) Bradykinin-antagonist peptide mit n- substituierten glycinen
ATE218142T1 (de) Nitratester von corticoid verbindungen und die therapeutische verwendungen davon
DE69625506D1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ATE203519T1 (de) Chinolinderivate als antimalariamittel
MXPA01010403A (es) Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
NO980296L (no) Forbedrede terapeutiske midler
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
ATE216881T1 (de) Zusammensetzung auf basis von enalapril und losartan
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
DE69428909D1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1097173

Country of ref document: EP

REN Ceased due to non-payment of the annual fee